A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast
Open Access
- 1 November 2018
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 98 (10), 975-976
- https://doi.org/10.2340/00015555-2995
Abstract
Is missing (Short commuication)...Keywords
This publication has 10 references indexed in Scilit:
- A case of severe pityriasis rubra pilaris with a dramatic response to apremilastEuropean Journal of Dermatology, 2018
- Essential Role of CARD14 in Murine Experimental PsoriasisThe Journal of Immunology, 2018
- Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)Journal of the American Academy of Dermatology, 2017
- Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor ApremilastJAMA Dermatology, 2016
- Treatment Options for Pityriasis Rubra Pilaris Including Biologic AgentsJAMA Dermatology, 2014
- Increased epidermal expression and absence of mutations inCARD14in a series of patients with sporadic pityriasis rubra pilarisBritish Journal of Dermatology, 2013
- Familial Pityriasis Rubra Pilaris Is Caused by Mutations in CARD14American Journal of Human Genetics, 2012
- Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in PsoriasisAmerican Journal of Human Genetics, 2012
- Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology, 2010
- The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-κB in HaCaT keratinocytesMolecular Immunology, 2009